Cell therapy weekly: Celyad to develop next-generation allogeneic CAR-T therapies
This week in cell therapy: Rare mechanism for cancer relapse after CAR-T reported, first results from Avrobio's Fabry disease gene therapy trial and development of a novel technique to generate OPCs.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>